Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors



Status:Recruiting
Conditions:Ovarian Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:June 2009

Use our guide to learn which trials are right for you!

A Non-Randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin With or Without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors


This phase II trial is studying alvocidib and oxaliplatin to see how well they work when
given with or without fluorouracil and leucovorin calcium in treating patients with relapsed
or refractory germ cell tumors. Drugs used in chemotherapy, such as alvocidib, oxaliplatin,
fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving alvocidib
together with oxaliplatin with or without fluorouracil and leucovorin calcium may kill more
tumor cells


PRIMARY OBJECTIVES:

I. To evaluate the antitumor efficacy of alvocidib and oxaliplatin with or without
fluorouracil and leucovorin calcium in patients with relapsed or refractory germ cell
tumors.

SECONDARY OBJECTIVES:

I. To further evaluate the safety of these regimens in these patients. II. To evaluate the
time to tumor response and progression-free survival of patients treated with these
regimens.

III. To explore the association between treatment response and p21, p53, and apoptotic
markers.

OUTLINE: Patients are initially enrolled in part A (closed to accrual as of 11/15/2010).
Depending on response to treatment, additional patients may be enrolled in part B.

PART A (alvocidib and oxaliplatin) (closed to accrual as of 11/15/2010): Patients receive
alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses
repeat every 42 days in the absence of disease progression or unacceptable toxicity.

PART B (alvocidib and FOLFOX): Patients receive alvocidib IV over 1 hour, oxaliplatin IV
over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV
continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the
absence of disease progression or unacceptable toxicity. Tumor tissue samples may be
collected periodically for further laboratory analysis.

After completion of study treatment, patients are followed up every 4-8 weeks.

Inclusion Criteria:

- Histologically confirmed germ cell tumor (GCT)

- Seminoma or non-seminoma

- Progressive disease after prior cisplatin-based therapy AND meets 1 of the following
criteria:

- Not considered to be a candidate for potentially curative therapy

- Previously treated with high-dose chemotherapy regimens

- Does not wish to undergo potentially curative high-dose therapy

- Measurable or evaluable disease, as defined by 1 of the following criteria:

- Unidimensionally measurable metastatic disease, defined as ≥ 1 malignant tumor
mass that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional
CT scan or MRI or as ≥ 10 mm by spiral CT scan

- Bone lesions, ascites, peritoneal carcinomatosis, miliary lesions, pleural
or pericardial effusions, lymphangitis of the skin or lung, cystic lesions,
or irradiated lesions are not considered measurable disease

- Patients with measurable disease only (i.e., normal tumor markers) must
have ≥ 1 site of disease that has not been previously irradiated

- Elevation of alpha-fetoprotein > 15 ng/mL and/or elevation of beta-human
chorionic gonadotropin > 2.2 mIU/L

- If tumor markers are not elevated, ≥ 1 site of measurable disease must be
present

- No known untreated CNS metastasis or primary CNS tumor

- Patients who have undergone local treatment for brain metastases and whose brain
metastases are demonstrated to be stable by repeat imaging studies performed ≥ 4
weeks after treatment are eligible

- Karnofsky performance status 70-100%

- ANC ≥ 1,000/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 8.0 g/dL

- Serum creatinine ≤ 2.0 times upper limit of normal (ULN)

- Total serum bilirubin ≤ 1.5 times ULN

- AST and ALT ≤ 2.5 times ULN (unless elevation is due to underlying malignancy)

- Not pregnant or nursing

- Negative pregnancy test by ultrasound

- Fertile patients must use effective contraception

- Willing and able to comply with scheduled study visits, treatment plans, laboratory
tests, follow-up tests for safety or effectiveness, and other study procedures

- Mediport or Broviac access required for patients enrolled in part B of the study

- No serious active infections

- No significant (≥ grade 2) or persistent ongoing toxicity, including peripheral
neuropathy, from prior therapy

- None of the following within the past 6 months:

- Myocardial infarction

- Severe/unstable angina

- Coronary/peripheral artery bypass graft

- Symptomatic congestive heart failure

- Cerebrovascular accident or transient ischemic attack

- Pulmonary embolism

- No contraindication to any of the study drugs

- No other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration, interfere with the interpretation of study results, and, in the
judgement of the investigator, may make the patient inappropriate for study entry

- No concurrent anti-retroviral therapy for HIV-positive patients

- Recovered from prior radiotherapy or surgery

- Residual grade 1 toxicities allowed

- No prior alvocidib

- At least 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C),
immunotherapy, or radiotherapy

- More than 4 weeks since prior major surgery

- No other concurrent approved or investigational anticancer treatment, including
surgery, radiotherapy, chemotherapy, biologic-response modifiers, hormone therapy, or
immunotherapy

- No concurrent participation in another investigational treatment clinical trial

- Concurrent participation in supportive care trials or non-treatment trials
(e.g., quality of life or laboratory analysis studies) allowed

- No concurrent vitamins, antioxidants, herbal preparations, or supplements, except for
a single-tablet multivitamin
We found this trial at
7
sites
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Los Angeles, California 90033
213) 740-2311
University of Southern California The University of Southern California is one of the world’s leading...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Beverly Hills, California 90211
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
4501 X St
Sacramento, California 95817
(916) 734-5800
UC Davis Comprehensive Cancer Center When faced with cancer, you want the best hope for...
?
mi
from
Sacramento, CA
Click here to add this to my saved trials